Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Selective synthesis of L-2-[18 F]fluoro-alpha-methylphenylalanine via copper mediated 18 F-fluorination of (mesityl)(aryl)iodonium salt.

Yamaguchi A, Hanaoka H, Higuchi T, Tsushima Y.

J Labelled Comp Radiopharm. 2020 Mar 27. doi: 10.1002/jlcr.3840. [Epub ahead of print]

PMID:
32221982
2.

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer.

Toyoda T, Kamata T, Tanaka K, Ihara F, Takami M, Suzuki H, Nakajima T, Ikeuchi T, Kawasaki Y, Hanaoka H, Nakayama T, Yoshino I, Motohashi S.

J Immunother Cancer. 2020 Mar;8(1). pii: e000316. doi: 10.1136/jitc-2019-000316.

3.

Diagnosis of bladder cancer using 18F-labeled α-methyl-phenylalanine tracers in a mouse model.

Mahendra I, Hanaoka H, Yamaguchi A, Amartuvshin T, Tsushima Y.

Ann Nucl Med. 2020 Mar 6. doi: 10.1007/s12149-020-01452-z. [Epub ahead of print]

PMID:
32144655
5.

Investigator-initiated clinical study of a functional peptide, SR-0379, for limb ulcers of patients with Werner syndrome as a pilot study.

Nakagami H, Sugimoto K, Ishikawa T, Koshizaka M, Fujimoto T, Kiyohara E, Hayashi M, Nakagawa Y, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Ebihara T, Nakamura A, Nishikawa M, Yao XJ, Hanaoka H, Yokote K, Rakugi H.

Geriatr Gerontol Int. 2019 Nov;19(11):1118-1123. doi: 10.1111/ggi.13782.

PMID:
31746528
6.

Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.

Yamaguchi A, Achmad A, Hanaoka H, Heryanto YD, Bhattarai A, Ratianto, Khongorzul E, Shintawati R, Kartamihardja AAP, Kanai A, Sugo Y, S Ishioka N, Higuchi T, Tsushima Y.

BMC Cancer. 2019 Oct 24;19(1):1000. doi: 10.1186/s12885-019-6238-4.

7.

A Systematic Review of Multimodal Non-Pharmacological Interventions for Cognitive Function in Older People with Dementia in Nursing Homes.

Yorozuya K, Kubo Y, Tomiyama N, Yamane S, Hanaoka H.

Dement Geriatr Cogn Disord. 2019;48(1-2):1-16. doi: 10.1159/000503445. Epub 2019 Oct 21.

8.

Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa.

Miura G, Sugawara T, Kawasaki Y, Tatsumi T, Nizawa T, Baba T, Hanaoka H, Yamamoto S.

Sci Rep. 2019 Aug 12;9(1):11668. doi: 10.1038/s41598-019-48158-5.

9.

Al18F-labeled alpha-melanocyte-stimulating hormone (α-MSH) peptide derivative for the early detection of melanoma.

Palangka CRAP, Hanaoka H, Yamaguchi A, Murakami T, Tsushima Y.

Ann Nucl Med. 2019 Oct;33(10):733-739. doi: 10.1007/s12149-019-01383-4. Epub 2019 Jul 5.

PMID:
31297699
10.

Novel 18F-Labeled α-Methyl-Phenylalanine Derivative with High Tumor Accumulation and Ideal Pharmacokinetics for Tumor-Specific Imaging.

Hanaoka H, Ohshima Y, Yamaguchi A, Suzuki H, Ishioka NS, Higuchi T, Arano Y, Tsushima Y.

Mol Pharm. 2019 Aug 5;16(8):3609-3616. doi: 10.1021/acs.molpharmaceut.9b00446. Epub 2019 Jul 10.

PMID:
31242385
11.

Study of aromas as reminiscence triggers in community-dwelling older adults in Japan.

Hanaoka H, Muraki T, Okamura H.

J Rural Med. 2019 May;14(1):87-94. doi: 10.2185/jrm.2982. Epub 2019 May 30.

12.

Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Clin Rheumatol. 2019 Oct;38(10):2785-2791. doi: 10.1007/s10067-019-04633-y. Epub 2019 Jun 7.

PMID:
31175481
13.

High plasma mycophenolate acid concentration in the early phase of induction therapy predicts good renal outcome in lupus nephritis.

Kiyokawa T, Hanaoka H, Iida H, Ishimori K, Takakuwa Y, Okazaki T, Ozaki S, Kawahata K.

Mod Rheumatol. 2019 Jun 13:1-8. doi: 10.1080/14397595.2019.1623435. [Epub ahead of print]

PMID:
31135249
14.

Preparation of 99mTc-Labeled Mannan-S-Cysteine and Effect of Molecular Size of Mannan on Its Biodistribution.

Hagiwara Y, Higashi K, Hagita H, Uehara T, Ito D, Hanaoka H, Suzuki H, Arano Y, Toida T.

Biol Pharm Bull. 2019;42(5):819-826. doi: 10.1248/bpb.b19-00026.

15.

Quantitative analysis of Gd in the protein content of the brain following single injection of gadolinium-based contrast agents (GBCAs) by size exclusion chromatography.

Kartamihardja AAP, Hanaoka H, Andriana P, Kameo S, Takahashi A, Koyama H, Tsushima Y.

Br J Radiol. 2019 Jul;92(1099):20190062. doi: 10.1259/bjr.20190062. Epub 2019 Jun 5.

PMID:
31045442
16.

Sivelestat sodium hydrate treatment for refractory Kawasaki disease.

Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N.

Pediatr Int. 2019 May;61(5):438-443. doi: 10.1111/ped.13851. Epub 2019 May 17.

PMID:
30916859
17.

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.

Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators.

Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Erratum in: Lancet. 2019 Mar 30;393(10178):1298. Lancet. 2019 Apr 13;393(10180):1504.

PMID:
30853151
18.

Adult-onset Still's disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse.

Takakuwa Y, Hanaoka H, Kiyokawa T, Iida H, Ishimori K, Uekusa T, Yamada H, Kawahata K.

Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):23-27. Epub 2019 Feb 11.

19.

A low perfusion-metabolic mismatch in 99m Tl and 123 I-BMIPP scintigraphy predicts poor prognosis in systemic sclerosis patients with asymptomatic cardiac involvement.

Iida H, Hanaoka H, Okada Y, Kiyokawa T, Takakuwa Y, Yamada H, Okazaki T, Ozaki S, Yamaguchi K, Nakajima Y, Kawahata K.

Int J Rheum Dis. 2019 Jun;22(6):1008-1015. doi: 10.1111/1756-185X.13508. Epub 2019 Feb 6.

PMID:
30729690
20.

Low-dose rituximab as induction therapy for ANCA-associated vasculitis.

Takakuwa Y, Hanaoka H, Kiyokawa T, Iida H, Fujimoto H, Yamasaki Y, Yamada H, Kawahata K.

Clin Rheumatol. 2019 Apr;38(4):1217-1223. doi: 10.1007/s10067-019-04443-2. Epub 2019 Jan 25.

PMID:
30680533
21.

Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Intern Med. 2019 May 1;58(9):1257-1262. doi: 10.2169/internalmedicine.1999-18. Epub 2019 Jan 10.

22.

Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.

Ishizaki A, Mishiro K, Shiba K, Hanaoka H, Kinuya S, Odani A, Ogawa K.

Ann Nucl Med. 2019 Apr;33(4):244-251. doi: 10.1007/s12149-018-01326-5. Epub 2019 Jan 3.

PMID:
30604401
23.

Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.

Takami A, Hirata K, Ishiguro C, Hanaoka H, Uyama Y.

Clin Pharmacol Ther. 2019 Jun;105(6):1471-1476. doi: 10.1002/cpt.1342. Epub 2019 Feb 10.

PMID:
30588617
24.

Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.

Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H.

ACS Cent Sci. 2018 Nov 28;4(11):1559-1569. doi: 10.1021/acscentsci.8b00565. Epub 2018 Nov 6.

25.

Thin-Shelled PEGylated Perfluorooctyl Bromide Nanocapsules for Tumor-Targeted Ultrasound Contrast Agent.

Achmad A, Yamaguchi A, Hanaoka H, Tsushima Y.

Contrast Media Mol Imaging. 2018 Nov 1;2018:1725323. doi: 10.1155/2018/1725323. eCollection 2018.

26.

Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Int J Rheum Dis. 2019 Mar;22(3):468-472. doi: 10.1111/1756-185X.13418. Epub 2018 Nov 8.

PMID:
30406967
27.

Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption.

Shrestha S, Sunaga H, Hanaoka H, Yamaguchi A, Kuwahara S, Umbarawan Y, Nakajima K, Machida T, Murakami M, Saito A, Tsushima Y, Kurabayashi M, Iso T.

Sci Rep. 2018 Nov 6;8(1):16451. doi: 10.1038/s41598-018-34902-w.

28.

A positive direct Coombs' test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Lupus. 2018 Dec;27(14):2274-2278. doi: 10.1177/0961203318809182. Epub 2018 Oct 25.

PMID:
30354857
29.

CD36 is indispensable for nutrient homeostasis and endurance exercise capacity during prolonged fasting.

Iso T, Haruyama H, Sunaga H, Matsui H, Matsui M, Tanaka R, Umbarawan Y, Syamsunarno MRAA, Putri M, Yamaguchi A, Hanaoka H, Negishi K, Yokoyama T, Kurabayashi M.

Physiol Rep. 2018 Sep;6(19):e13884. doi: 10.14814/phy2.13884.

30.

Mycophenolate mofetil treatment with or without a calcineurin inhibitor in resistant inflammatory myopathy.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Clin Rheumatol. 2019 Feb;38(2):585-590. doi: 10.1007/s10067-018-4294-9. Epub 2018 Sep 14.

PMID:
30218287
31.

Effects of olfactory stimulation on reminiscence practice in community-dwelling elderly individuals.

Hanaoka H, Muraki T, Ede J, Yasuhara K, Okamura H.

Psychogeriatrics. 2018 Jul;18(4):283-291. doi: 10.1111/psyg.12322.

PMID:
30133940
32.

Myocardial fatty acid uptake through CD36 is indispensable for sufficient bioenergetic metabolism to prevent progression of pressure overload-induced heart failure.

Umbarawan Y, Syamsunarno MRAA, Koitabashi N, Obinata H, Yamaguchi A, Hanaoka H, Hishiki T, Hayakawa N, Sano M, Sunaga H, Matsui H, Tsushima Y, Suematsu M, Kurabayashi M, Iso T.

Sci Rep. 2018 Aug 13;8(1):12035. doi: 10.1038/s41598-018-30616-1.

33.

Intravenous nicorandil versus adenosine for fractional flow reserve measurement: a crossover, randomized study.

Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y.

Heart Vessels. 2018 Dec;33(12):1570-1575. doi: 10.1007/s00380-018-1197-2. Epub 2018 Jun 1.

PMID:
29858919
34.

Activatable fluorescence detection of epidermal growth factor receptor positive mediastinal lymph nodes in murine lung cancer model.

Zhang X, Nakajima T, Kim M, Yamaguchi A, Lamid-Ochir O, Nguyen-Thu H, Bhattarai A, Hanaoka H, Tsushima Y.

PLoS One. 2018 Jun 1;13(6):e0198224. doi: 10.1371/journal.pone.0198224. eCollection 2018.

35.

Conversion of iodine to fluorine-18 based on iodinated chalcone and evaluation for β-amyloid PET imaging.

Kaide S, Ono M, Watanabe H, Shimizu Y, Nakamoto Y, Togashi K, Yamaguchi A, Hanaoka H, Saji H.

Bioorg Med Chem. 2018 Jul 23;26(12):3352-3358. doi: 10.1016/j.bmc.2018.05.001. Epub 2018 May 3.

PMID:
29751990
36.

Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.

Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y.

Mol Pharm. 2018 Jun 4;15(6):2165-2173. doi: 10.1021/acs.molpharmaceut.8b00027. Epub 2018 May 23.

PMID:
29733658
37.

Study protocol for the G-SPIRIT trial: a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury.

Koda M, Hanaoka H, Sato T, Fujii Y, Hanawa M, Takahashi S, Furuya T, Ijima Y, Saito J, Kitamura M, Ohtori S, Matsumoto Y, Abe T, Watanabe K, Hirano T, Ohashi M, Shoji H, Mizouchi T, Takahashi I, Kawahara N, Kawaguchi M, Orita Y, Sasamoto T, Yoshioka M, Fujii M, Yonezawa K, Soma D, Taneichi H, Takeuchi D, Inami S, Moridaira H, Ueda H, Asano F, Shibao Y, Aita I, Takeuchi Y, Mimura M, Shimbo J, Someya Y, Ikenoue S, Sameda H, Takase K, Ikeda Y, Nakajima F, Hashimoto M, Ozawa T, Hasue F, Fujiyoshi T, Kamiya K, Watanabe M, Katoh H, Matsuyama Y, Yamamoto Y, Togawa D, Hasegawa T, Kobayashi S, Yoshida G, Oe S, Banno T, Arima H, Akeda K, Kawamoto E, Imai H, Sakakibara T, Sudo A, Ito Y, Kikuchi T, Osaki S, Tanaka N, Nakanishi K, Kamei N, Kotaka S, Baba H, Okudaira T, Konishi H, Yamaguchi T, Ito K, Katayama Y, Matsumoto T, Matsumoto T, Idota M, Kanno H, Aizawa T, Hashimoto K, Eto T, Sugaya T, Matsuda M, Fushimi K, Nozawa S, Iwai C, Taguchi T, Kanchiku T, Suzuki H, Nishida N, Funaba M, Yamazaki M.

BMJ Open. 2018 May 5;8(5):e019083. doi: 10.1136/bmjopen-2017-019083.

38.

Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Okazaki T, Yamada H, Ozaki S, Kawahata K.

PLoS One. 2018 May 3;13(5):e0196172. doi: 10.1371/journal.pone.0196172. eCollection 2018.

39.

Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K.

Arthritis Res Ther. 2018 May 2;20(1):86. doi: 10.1186/s13075-018-1576-1. No abstract available.

40.

A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.

Uehara T, Yokoyama M, Suzuki H, Hanaoka H, Arano Y.

Clin Cancer Res. 2018 Jul 15;24(14):3309-3316. doi: 10.1158/1078-0432.CCR-18-0123. Epub 2018 Apr 17.

41.

Glucose is preferentially utilized for biomass synthesis in pressure-overloaded hearts: evidence from fatty acid-binding protein-4 and -5 knockout mice.

Umbarawan Y, Syamsunarno MRAA, Koitabashi N, Yamaguchi A, Hanaoka H, Hishiki T, Nagahata-Naito Y, Obinata H, Sano M, Sunaga H, Matsui H, Tsushima Y, Suematsu M, Kurabayashi M, Iso T.

Cardiovasc Res. 2018 Jul 1;114(8):1132-1144. doi: 10.1093/cvr/cvy063.

42.

Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial.

Nakagami H, Sugimoto K, Ishikawa T, Fujimoto T, Yamaoka T, Hayashi M, Kiyohara E, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Koshizaka M, Ebihara T, Nakamura A, Nishikawa M, Yao XJ, Hanaoka H, Katayama I, Yokote K, Rakugi H.

NPJ Aging Mech Dis. 2018 Feb 13;4:2. doi: 10.1038/s41514-018-0021-7. eCollection 2018.

43.
44.

Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET.

Nguyen-Thu H, Hanaoka H, Nakajima T, Yamaguchi A, Nguyen-Cong T, Kartamihardja AAP, Tsushima Y.

Breast Cancer. 2018 May;25(3):334-342. doi: 10.1007/s12282-018-0834-z. Epub 2018 Jan 22.

PMID:
29357023
45.

Coordination-Mediated Synthesis of Purification-Free Bivalent 99mTc-Labeled Probes for in Vivo Imaging of Saturable System.

Taira Y, Uehara T, Tsuchiya M, Takemori H, Mizuno Y, Takahashi S, Suzuki H, Hanaoka H, Akizawa H, Arano Y.

Bioconjug Chem. 2018 Feb 21;29(2):459-466. doi: 10.1021/acs.bioconjchem.7b00788. Epub 2018 Jan 31.

PMID:
29320158
46.

Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.

Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, Nakagomi D, Hiraguri M, Hanaoka H, Sato Y, Ikeda K, Nakajima H; LoVAS Trial study investigators.

BMJ Open. 2017 Dec 14;7(12):e018748. doi: 10.1136/bmjopen-2017-018748. Erratum in: BMJ Open. 2018 Jan 21;8(1):e018748corr1.

47.

Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model.

Shinohara A, Hanaoka H, Sakashita T, Sato T, Yamaguchi A, Ishioka NS, Tsushima Y.

Ann Nucl Med. 2018 Feb;32(2):114-122. doi: 10.1007/s12149-017-1225-9. Epub 2017 Dec 13.

PMID:
29238922
48.

Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.

Yamaguchi A, Hanaoka H, Higuchi T, Tsushima Y.

J Nucl Med. 2018 May;59(5):815-821. doi: 10.2967/jnumed.117.201525. Epub 2017 Dec 7.

49.

Rhabdomyolysis in a Patient with Polyarteritis Nodosa.

Iida H, Hanaoka H, Asari Y, Ishimori K, Kiyokawa T, Takakuwa Y, Yamasaki Y, Yamada H, Okazaki T, Doi M, Ozaki S.

Intern Med. 2018 Jan 1;57(1):101-106. doi: 10.2169/internalmedicine.8913-17. Epub 2017 Oct 11.

50.

Robust suppression of cardiac energy catabolism with marked accumulation of energy substrates during lipopolysaccharide-induced cardiac dysfunction in mice.

Umbarawan Y, Syamsunarno MRAA, Obinata H, Yamaguchi A, Sunaga H, Matsui H, Hishiki T, Matsuura T, Koitabashi N, Obokata M, Hanaoka H, Haque A, Kunimoto F, Tsushima Y, Suematsu M, Kurabayashi M, Iso T.

Metabolism. 2017 Dec;77:47-57. doi: 10.1016/j.metabol.2017.09.003. Epub 2017 Sep 20.

Supplemental Content

Loading ...
Support Center